IFNB1 and in situ carcinoma: Patients who started IFNB-1b at CIS retained a lower risk for conversion to clinically definite multiple sclerosis (CDMS) and a lower annualized relapse rate (ARR) compared with those who started IFNB-1b after a short delay (mean 1.5 years) [5].